Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Unraveling heterogeneity within ACPA-negative rheumatoid arthritis: the subgroup of patients with a strong clinical and serological response to initiation of DMARD treatment favor disease resolution

Fig. 4

Biomarker response after DMARD start is stronger in ACPA-negative RA patients with early DAS remission.

ACPA-negative RA patients with a DAS4 months < 1.6 demonstrated a significantly stronger median decline in MMP-1, SAA, and CRP in the first year after DMARD initiation. *p < 0.05. CRP, C-reactive protein; MMP, matrix metalloproteinase; SAA, serum A amyloid; SDFR, sustained DMARD-free remission

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us